Scandella D, Mattingly M, de Graaf S, Fulcher C A
Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross Blood Services, Rockville, MD.
Blood. 1989 Oct;74(5):1618-26.
Human factor VIII(FVIII) inhibitors are pathologic, circulating antibodies that inactivate FVIII. We have examined the location of epitopes on the FVIII protein for inhibitors from hemophilia A and nonhemophilic individuals. The inhibitors were of type I or type II in the kinetics of their inactivation of FVIII. A cDNA clone of human FVIII was used to express defined FVIII protein fragments in Escherichia coli for immunoblotting with inhibitor plasma. An epitope for 18 heavy-chain inhibitors was localized to the aminoterminal 18.3 Kd of the A2 domain. Two of these inhibitors also recognized an epitope located between A1 and A2 domains. Similarly, an epitope for 23 light-chain inhibitors was localized to the C2 domain. Weaker epitopes for 13 of the same inhibitors within the C1 and C2 domains were also observed. Four of the 23 inhibitors in addition bound strongly to the A3 domain. Most inhibitors (22 of 23) were neutralized in vitro only by the FVIII fragments to which they bound on immunoblots; however, one inhibitor that was neutralized by a fragment containing the A1 domain did not bind to it on immunoblots. Conversely, 3 of 3 inhibitors that bound to the A3 domain and 5 of 15 that bound to the A2 domain were not neutralized by the corresponding fragments. The epitope specificity of an inhibitor did not depend on its source or type. Our results show that FVIII inhibitors bind to limited areas within the heavy and light chains of FVIII. Some inhibitor plasmas contain additional antibodies that may not be inhibitory.
人凝血因子VIII(FVIII)抑制剂是使FVIII失活的病理性循环抗体。我们已经研究了来自甲型血友病患者和非血友病个体的抑制剂在FVIII蛋白上的表位位置。这些抑制剂在使FVIII失活的动力学方面属于I型或II型。利用人FVIII的cDNA克隆在大肠杆菌中表达特定的FVIII蛋白片段,用于与抑制剂血浆进行免疫印迹分析。18种重链抑制剂的一个表位定位于A2结构域氨基末端18.3Kd处。其中两种抑制剂还识别位于A1和A2结构域之间的一个表位。同样,23种轻链抑制剂的一个表位定位于C2结构域。在C1和C2结构域内也观察到其中13种相同抑制剂的较弱表位。23种抑制剂中有4种还与A3结构域强烈结合。大多数抑制剂(23种中的22种)在体外仅被它们在免疫印迹上结合的FVIII片段中和;然而,一种被含A1结构域的片段中和的抑制剂在免疫印迹上并不与之结合。相反,与A3结构域结合的3种抑制剂中的3种以及与A2结构域结合的15种抑制剂中的5种未被相应片段中和。抑制剂的表位特异性不取决于其来源或类型。我们的结果表明,FVIII抑制剂结合于FVIII重链和轻链内的有限区域。一些抑制剂血浆含有可能不具有抑制作用的额外抗体。